Back to top
more

Catalyst Pharmaceuticals (CPRX)

(Delayed Data from NSDQ)

$31.38 USD

31.38
3,352,548

-0.02 (-0.06%)

Updated Jun 18, 2026 03:59 PM ET

After-Market: $31.38 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 247)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Thermo Fisher (TMO) Opens New Cell Therapy Facility at UCSF

by Zacks Equity Research

Thermo Fisher's (TMO) new cell therapy facility at UCSF is likely to accelerate the development of advanced therapies.

Zacks Equity Research

Catalyst Pharmaceutical (CPRX) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Catalyst Pharmaceutical (CPRX) closed at $16.44, marking a +1.99% move from the previous day.

Zacks Equity Research

Encompass Health (EHC) Opens JV Hospital for Oklahoma Patients

by Zacks Equity Research

Encompass Health (EHC) inaugurated the Owasso-based Ascension St. John Rehabilitation Hospital, that it will operate jointly with Ascension St. John to offer rehabilitative care in Oklahoma.

Zacks Equity Research

Walgreens Boots (WBA) Benefits From Innovation Amid Margin Woe

by Zacks Equity Research

Walgreens Boots' (WBA) comparable pharmacy sales decline reflects lower demand for COVID-19 services.

Zacks Equity Research

Abbott's (ABT) CardioMEMS Favors Heart Failure Management

by Zacks Equity Research

Abbott (ABT) announces key findings from meta-analysis, which shows remote pressure monitoring to be a life-extending option among heart failure patients.

Zacks Equity Research

Globus Medical (GMED) to Gain From NUVA Deal Amid Rising Costs

by Zacks Equity Research

The NuVasive acquisition aims to outpace market growth by combining Globus Medical's (GMED) engineering and NuVasive's relations, education and training.

Zacks Equity Research

Smith & Nephew's (SNN) CIT Technology Favored by New Study

by Zacks Equity Research

Smith & Nephew (SNN) achieves a positive response for its COBLATION-Technology-infused Intracapsular Tonsillectomy Technique, providing fast patient recovery over existing surgeries.

Zacks Equity Research

Syneos Health (SYNH) Partners With KX for Data-Driven Insights

by Zacks Equity Research

Syneos Health's (SYNH) partnership with KX is likely to accelerate clinical trial execution using AI-enabled solutions.

Zacks Equity Research

Wall Street Analysts Think Catalyst (CPRX) Could Surge 26.44%: Read This Before Placing a Bet

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 26.4% in Catalyst (CPRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

Zacks.com featured highlights include Catalyst Pharmaceuticals, Terex and Arista Networks

by Zacks Equity Research

Catalyst Pharmaceuticals, Terex and Arista Networks are part of the Zacks Screen of the Week article.